Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer

Clinical Cancer Research

Volumn 9, Issue 1 I, 2003, Pages 285-294

  Bin, Yu ^a   Kusmartsev, Sergei ^a   Fengdong, Cheng ^a   Paolini, Maria ^a   Nefedova, Yulia ^a   Sotomayor, Eduardo ^a   Gabrilovich, Dmitry ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CONCANAVALIN A; DEXAMETHASONE; EPITOPE; INFLUENZA VIRUS HEMAGGLUTININ; LIPOCORTIN 5; MONOCLONAL ANTIBODY; PACLITAXEL; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DENDRITIC CELL; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD28; ANTIGENS, CD4; ANTIGENS, CD8; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; DENDRITIC CELLS; DEXAMETHASONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; FLOW CYTOMETRY; IMMUNOTHERAPY; IN SITU NICK-END LABELING; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; T-LYMPHOCYTES; TIME FACTORS;

EID: 0037239826     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Fuchs, E. J., Bedi, A., Jones, R. J., and Hess, A. D. Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis. Cancer Res., 55: 463-466, 1995.
2. Shtil, A. A., Turner, J. G., Durfee, J., Dalton, W. S., and Yu, H. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes. Blood, 93: 1831-1837, 1999.
3. Albert, M. L., Birthe, S., and Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (Lond.), 392: 86-89, 1998.
4. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med., 188: 1359-1368, 1998.
5. Jenne, L., Arrighi, J., Jonuleit, H., Saurat, J., and Hauser, C. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res., 60: 4446-4452, 2000.
6. Nouri-Shirazi, M., Banchereau, J., Bell, D., Burkeholder, S., Kraus, E., Davoust, J., and Palucka, K. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol., 165: 3797-3803, 2000.
7. Restifo, N. P. Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr. Opin. Immunol., 12: 597-603, 2000.
8. Sauter, B., Albert, M. L., Francisco, L., Larsson, M., Somersan, S., and Bhardwaj, N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med., 191: 423-433, 2000.
9. Candido, K. A., Shimizu, K., McLaughlin, J. C., Kunkel, R., Fuller, R., Redman, B. G., Thomas, E. K., Nickoloff, B. J., and Mule, J. J. Local administration of dendritic cells inhibits established breast tumor growth: implication for apoptosis-inducing agents. Cancer Res., 61: 228-236, 2001.
10. Nikitina, E. Y., and Gabrilovich, D. I. Combination of γ irradiation and dendritic cell administration in treatment of advanced cancer. Intern. J. Cancer, 94: 825-833, 2001.
11. Tong, Y., Song, W., and Crystal, R. G. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existed murine tumors. Cancer Res., 61: 7530-7535, 2001.
12. Sotomayor, E. M., Fu, Y. X., Lopez-Cepero, M., Herbert, L., Jimenez, J. J., Albarracin, C., and Lopez, D. M. Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. II. Down-regulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor. J. Immunol., 147: 2816-2823, 1991.
13. Levitsky, H. I., Lazenby, A., Hayashi, R. J., and Pardoll, D. M. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J. Exp. Med., 179: 1215-1224, 1994.
14. Morgan, D. J., Kreuwel, H. T., Fleck, S., Levitsky, H. I., Pardoll, D. M., and Sherman, L. A. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol., 160: 643, 1998.
15. Gabrilovich, D. I., Velders, M., Sotomayor, E., and Kast, W. M. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J. Immunol., 166: 5398-5406, 2001.
16. Sotomayor, E. M., Borrello, I., Tubb, E., Rattis, F. M., Bien, H., Lu, Z., Fein, S., Schoenberger, S., and Levitsky, H. I. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med., 5: 780-787, 1999.
17. Staveley-O'Corrol, K., Sotomayor, E., Mongomery, J., Borrelo, I., Hwang, L., Fein, S., Pardoll, D., and Levitsky, H. Induction of antigenspecific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA, 95: 1178-1183, 1998.
18. Shah, M. A., and Schwartz, G. K. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin. Cancer Res., 7: 2168-2181, 2001.
19. Keilholz, U., Weber, J., Finke, J., Gabrilovich, D., Kast, M., Disis, N., Kirkwood, J., Scheibenbogen, C., Schlom, J., Maino, V., Lyerly, M., Lee, P., Storkus, W., Marincola, F., Worobecand, A., and Atkins, W. B. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the society for biologic therapy. J. Immunother., 25: 97-139, 2002.
20. Harris, J., Sengar, D., Stewart, T., and Hyslop, D. The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease. Cancer (Phila.), 37 (Suppl.): 1058-1069, 1976.
21. Mokyr, M. B., and Dray, S. Interplay between the toxic effects of anticancer drugs and host antitumor immunity in cancer therapy. Cancer Investig., 5: 31-38, 1987.
22. Oliver, R. T., and Nouri, A. M. T cell immune response to cancer in humans and its relevance for immunodiagnosis and therapy. Cancer Surv., 13: 173-204, 1992.